Splicing analyses for variants in MMR genes: best practice recommendations from the European Mismatch Repair Working Group.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
09 2022
Historique:
received: 25 09 2021
accepted: 11 04 2022
revised: 20 03 2022
pubmed: 9 6 2022
medline: 9 9 2022
entrez: 8 6 2022
Statut: ppublish

Résumé

Over 20% of the DNA mismatch repair (MMR) germline variants in suspected Lynch syndrome patients are classified as variants of uncertain significance (VUS). Well-established functional assays are pivotal for assessing the biological impact of these variants and provide relevant evidence for clinical classification. In our collaborative European Mismatch Repair Working Group (EMMR-WG) we compared three different experimental approaches for evaluating the effect of seven variants on mRNA splicing in MMR genes: (i) RT-PCR of full-length transcripts (FLT), (ii) RT-PCR of targeted transcript sections (TTS), both from patient biological samples and (iii) minigene splicing assays. An overall good concordance was observed between splicing patterns in TTS, FLT and minigene analyses for all variants. The FLT analysis depicted a higher number of different isoforms and mitigated PCR-bias towards shorter isoforms. TTS analyses may miss aberrant isoforms and minigene assays may under/overestimate the severity of certain splicing defects. The interpretation of the experimental findings must be cautious to adequately discriminate abnormal events from physiological complex alternative splicing patterns. A consensus strategy for investigating the impact of MMR variants on splicing was defined. First, RNA should be obtained from patient's cell cultures (such as fresh lymphocyte cultures) incubated with/without a nonsense-mediated decay inhibitor. Second, FLT RT-PCR analysis is recommended to oversee all generated isoforms. Third, TTS analysis and minigene assays are useful independent approaches for verifying and clarifying FLT results. The use of several methodologies is likely to increase the strength of the experimental evidence which contributes to improve variant interpretation.

Identifiants

pubmed: 35676339
doi: 10.1038/s41431-022-01106-w
pii: 10.1038/s41431-022-01106-w
pmc: PMC9437034
doi:

Substances chimiques

Protein Isoforms 0
DNA Repair Enzymes EC 6.5.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1051-1059

Informations de copyright

© 2022. The Author(s).

Références

Hum Mutat. 2012 Nov;33(11):1576-88
pubmed: 22736432
PLoS Genet. 2016 Jan 13;12(1):e1005756
pubmed: 26761715
Hum Mutat. 2014 Jan;35(1):53-7
pubmed: 24123850
Eur J Hum Genet. 2000 May;8(5):347-52
pubmed: 10854094
Hum Mutat. 2019 Dec;40(12):2296-2317
pubmed: 31343793
Dis Markers. 2004;20(4-5):269-76
pubmed: 15528792
Hum Mutat. 2017 Jan;38(1):64-77
pubmed: 27629256
Nucleic Acids Res. 2003 Jul 1;31(13):3568-71
pubmed: 12824367
Clin Genet. 2015 Feb;87(2):100-8
pubmed: 24989436
Front Genet. 2020 Jul 27;11:798
pubmed: 32849802
J Med Genet. 1999 Nov;36(11):801-18
pubmed: 10544223
Prog Mol Subcell Biol. 2006;44:65-87
pubmed: 17076265
Hum Genet. 2006 Mar;119(1-2):9-22
pubmed: 16341550
Methods Mol Biol. 2012;867:49-63
pubmed: 22454054
Front Genet. 2018 Sep 05;9:366
pubmed: 30233647
Hum Mol Genet. 2016 Jun 1;25(11):2256-2268
pubmed: 27008870
Am J Hum Genet. 2021 Jan 7;108(1):163-175
pubmed: 33357406
Hum Mutat. 2012 Aug;33(8):1228-38
pubmed: 22505045
Genet Med. 2020 Jul;22(7):1235-1246
pubmed: 32307445
Eur J Hum Genet. 2021 Apr;29(4):680-686
pubmed: 33293698
Commun Biol. 2020 Jul 30;3(1):403
pubmed: 32732980
Hum Mutat. 2006 Feb;27(2):145-54
pubmed: 16395668
Nucleic Acids Res. 1999 Sep 15;27(18):e23
pubmed: 10471753
Hum Mutat. 2008 Nov;29(11):1304-13
pubmed: 18951448
BMC Genomics. 2006 Sep 22;7:243
pubmed: 16995940
Hum Genet. 1998 Jan;102(1):15-20
pubmed: 9490293
Clin Chem. 2014 Feb;60(2):341-52
pubmed: 24212087
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Hum Mutat. 2008 Dec;29(12):1412-24
pubmed: 18561205
Eur J Hum Genet. 2019 Dec;27(12):1808-1820
pubmed: 31332305
Methods Mol Biol. 2010;653:249-57
pubmed: 20721748
Eur J Med Res. 2001 Nov 20;6(11):473-82
pubmed: 11726306
Nucleic Acids Res. 2018 Sep 6;46(15):7913-7923
pubmed: 29750258
PLoS Genet. 2018 Mar 5;14(3):e1007231
pubmed: 29505604
Cancer Res. 1995 May 1;55(9):1839-41
pubmed: 7728749
Int J Cancer. 2017 Oct 1;141(7):1365-1380
pubmed: 28577310
Hum Mutat. 2020 Oct;41(10):1811-1829
pubmed: 32741062
Nat Genet. 2014 Feb;46(2):107-115
pubmed: 24362816
J Med Genet. 2012 Oct;49(10):609-17
pubmed: 22962691
Fam Cancer. 2006;5(2):195-9
pubmed: 16736291
Mol Genet Genomic Med. 2015 Jul;3(4):327-45
pubmed: 26247049

Auteurs

Monika Morak (M)

Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
MGZ - Medizinisch Genetisches Zentrum, Munich, Germany.

Marta Pineda (M)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.

Alexandra Martins (A)

Inserm U1245, UNIROUEN, Normandie Univ, F-76000, Rouen, France.

Pascaline Gaildrat (P)

Inserm U1245, UNIROUEN, Normandie Univ, F-76000, Rouen, France.

Hélène Tubeuf (H)

Inserm U1245, UNIROUEN, Normandie Univ, F-76000, Rouen, France.
Interactive Biosoftware, Rouen, France.

Aurélie Drouet (A)

Inserm U1245, UNIROUEN, Normandie Univ, F-76000, Rouen, France.

Carolina Gómez (C)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain.

Estela Dámaso (E)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain.

Kerstin Schaefer (K)

Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.

Verena Steinke-Lange (V)

Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany.
MGZ - Medizinisch Genetisches Zentrum, Munich, Germany.

Udo Koehler (U)

MGZ - Medizinisch Genetisches Zentrum, Munich, Germany.

Andreas Laner (A)

MGZ - Medizinisch Genetisches Zentrum, Munich, Germany.

Julie Hauchard (J)

Inserm U1245, UNIROUEN, Normandie Univ, F-76000, Rouen, France.

Karine Chauris (K)

Inserm U1245, UNIROUEN, Normandie Univ, F-76000, Rouen, France.

Elke Holinski-Feder (E)

Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Munich, Germany. elke.holinskifeder@med.uni-muenchen.de.
MGZ - Medizinisch Genetisches Zentrum, Munich, Germany. elke.holinskifeder@med.uni-muenchen.de.

Gabriel Capellá (G)

Hereditary Cancer Program, Catalan Institute of Oncology-IDIBELL, ONCOBELL Program, L'Hospitalet, Barcelona, Spain. gcapella@idibell.cat.
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. gcapella@idibell.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH